



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07H 21/00, C12Q 1/68	A1	(11) International Publication Number: WO 92/21693 (43) International Publication Date: 10 December 1992 (10.12.92)
(21) International Application Number: PCT/US92/04195 (22) International Filing Date: 27 May 1992 (27.05.92) (30) Priority data: 707,501 29 May 1991 (29.05.91) US 799,828 27 November 1991 (27.11.91) US (71) Applicant: THE UNITED STATES OF AMERICA, as presented by THE SECRETARY OF THE DEPART- MENT OF HEALTH AND HUMAN SERVICES [US/ US]; Washington, D.C. 20201 (US). (72) Inventors: POLYMERPOULOS, Michael, H. ; 477 Bat- tery Lane, #420, Bethesda, MD 20814 (US). MERRILL, Carl, R. ; 2 Winder Court, Rockville, MD 20850 (US).		(74) Agents: PRICE, Robert, L. et al.; Lowe, Price, Leblanc, Becker, 99 Canal Center Plaza, Suite 300, Alexandria, VA 22314 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CA, CH (European patent), DE (Euro- pean patent), DK (European patent), ES (European pa- tent), FR (European patent), GB (European patent), GR (European patent), IT (European patent), JP, LU (Euro- pean patent), MC (European patent), NL (European pa- tent), SE (European patent). Published <i>With international search report.</i>
(54) Title: THREE HIGHLY INFORMATIVE MICROSATELLITE REPEAT POLYMORPHIC DNA MARKERS (57) Abstract <p>The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms and 27 markers characterized by primer pairs 1A-27A) that are useful for human individualization. Applications are in forensic medicine and for paternity and prenatal screening as well as genetic mapping. These markers are characterized by sets of oligonucleotide primers according to the invention useful in PCR amplification and DNA segment resolution. The invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms which comprises obtaining an amount of nucleotide segments effective for testing, amplifying the segments by the PCR procedure using at least one primer nucleotide sequence according to the present invention, resolving the amplified segments using gel electrophoresis, and comparing the resolved segments by autoradiography to observe the differences in migration patterns due to structural differences. The assay according to the invention is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. Accordingly, the invention also relates to an improved PCR procedure and a PCR assay kit which comprise nucleotides according to the invention.</p>		

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FI	Finland	MI	Mali
AU	Australia	FR	France	MN	Mongolia
BB	Barbados	GA	Gabon	MR	Mauritania
BE	Belgium	GB	United Kingdom	MW	Malawi
BF	Burkina Faso	GN	Guinea	NI	Netherlands
BG	Bulgaria	GR	Greece	NO	Norway
BJ	Benin	HU	Hungary	PL	Poland
BR	Brazil	IE	Ireland	RO	Romania
CA	Canada	IT	Italy	RU	Russian Federation
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CI	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TC	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark	MG	Madagascar		
ES	Spain				

THREE HIGHLY INFORMATIVE MICROSATELLITE REPEAT
POLYMORPHIC DNA MARKERS

Technical Field

This application relates to genetic testing with polymorphic DNA markers having repeat sequences to provide a rapid and convenient high resolution process for distinguishing target nucleic acid segments on the basis of nucleotide differences according to human individualization wherein the nucleic acid segments differ in size.

Background Art

The science of genetics has taken a keen interest in the identification of human individualization and genetic relationships between individuals. Each individual has hereditary material (DNA, "nucleotides") which is unique to that individual and hereditary material which is related to that of others. Procedures have been developed which are based on identification and characterization of changes in DNAs, which are changes in DNA (DNA polymorphisms) due to nucleotide substitution, insertion, or deletion within the chains of DNAs.

In the field of forensic medicine, for example, there is a keen interest in such polymorphisms for identification purposes. Forensic geneticist have developed many techniques to compare homologous

segments of DNA to determine if the segments are identical or if they differ in one or more nucleotides. Practical applications of these techniques relate to fields other than forensic medicine, for example, genetic disease diagnosis and human genome mapping.

At the present time in this art, the most accurate and informative way to compare DNA segments requires a method which provides the complete nucleotide sequence for each DNA segment. Particular techniques have been developed for determining actual sequences in order to study mutation in human genes. See, for example, Proc. Natl. Acad. Sci. U.S.A. 85, 544-548 (1988) and Nature 330, 384-386 (1987). However, because of the extensive amounts of time and high costs to determine, interpret, and compare sequence information, presently it is not practical to use extensive sequencing for compare more than just a few DNA segments.

In genetic mapping, the most frequently used screening for DNA polymorphisms arising from mutations consist of digesting the DNA strand with restriction endonucleases and analyzing the resulting fragments by means of Southern blots. See Am. J. Hum. Genet. 32, 314-331 (1980) or Sci. Am. 258, 40-48 (1988). Since mutations often occur randomly they may affect the recognition sequence of the endonuclease and preclude the enzymatic cleavage at that cite. Restriction fragment length polymorphism mappings (RFLPS) are based on changes at the restriction site. They are accurate but not very informative (PIC [0.3). The major problem with RFLPs is the inability of a test to detect changes that do not affect cleavage with a restriction endonuclease. As in many of the test methods in the DNA art, the methods used to detect

RFLPs are very labor intensive and expensive, especially the techniques which includes Southern blot analysis.

Another technique for detecting specific mutations in particular DNA segment involves hybridizing DNA segments which are being analyzed (target DNA) with a complimentary, labeled oligonucleotide probe. See Nucl. Acids Res. 9, 879-894 (1981). Since DNA duplexes containing even a single base pair mismatch exhibit high thermal instability, the differential melting temperature can be used to distinguish target DNAs that are perfectly complimentary to the probe from target DNAs that only differ by a single nucleotide. This method has been adapted to detect the presence or absence of a specific restriction site, U.S. Patent No. 4,683,194. The method involves using an end-labeled oligonucleotide probe spanning a restriction site which is hybridized to a target DNA. The hybridized duplex of DNA is then incubated with the restriction enzyme appropriate for that site. Reform restriction sites will be cleaved by digestion in the pair of duplexes between the probe and target by using the restriction endonuclease. The specific restriction site is present in the target DNA if shortened probe molecules are detected.

Another process for studying differences in DNA structure is the primer extension process which consists of hybridizing a labeled oligonucleotide primer to a template RNA or DNA and then using a DNA polymerase and deoxynucleoside triphosphates to extend the primer to the 5' end of the template. Resolution of the labeled primer extension product is then done by fractionating on the basis of size, e.g., by electrophoresis via a denaturing polyacrylamide gel.

This process is often used to compare homologous DNA segments and to detect differences due to nucleotide insertion or deletion. Differences due to nucleotide substitution are not detected since size is the sole criterion used to characterize the primer extension product.

Another process exploits the fact that the incorporation of some nucleotide analogs into DNA causes an incremental shift of mobility when the DNA is subjected to a size fractionation process, such as electrophoresis. Nucleotide analogs can be used to identify changes since they can cause an electrophoretic mobility shift. See, U.S. Patent 4,879,214.

Unfortunately, the above techniques used for identification of polymorphisms are either not very informative or take a long period of time to perform. For example, techniques which identify changes in individual nucleotides on a particular DNA strand often take at least three to four days to perform. Accordingly, such tests are very labor intensive and expensive to perform.

Further, subtle genetic differences among related individuals regarding nucleotides which are substituted in the DNA chains are difficult to detect. VNTR's or Jeffrey's probes (which the FBI is using to test and identify DNA chains) are very informative but labor intensive, in distinction to microsatellites as our which are equally informative PCR based polymorphismic.

The use of certain nucleotide repeat polymorphisms for identifying or comparing DNA segments have been described by Weber & May 89 Am Hum Genet 44:388, Litt & Luthy '89 Am Hum Genet 44:397). However the particular polymorphism genetic segments and primers used to identify the polymorphisms (for identification

and comparison purposes) of the present invention have not been previously known or suspected.

Accordingly, there is a need in this art for a rapid, simple, inexpensive and accurate technique having a very high resolution value to determine relationships between individuals and differences in degree of relationships. Also, there is a need in the art for a very accurate genetic relationship test procedure which uses very small amounts of an original DNA sample, yet produces very accurate results. This is particularly true in the forensic medicine area and criminology, since often times very small samples of DNA are available for testing.

Disclosure of the Invention

An object of the present invention is to provide a fast and accurate test for measuring the subtle differences in individuals by way of genetic testing.

Another object of the invention relates to polymorphic markers that can be used for human individualization.

A further object of the invention is to provide a fast and accurate technique for measuring the subtle differences in individuals by way of genetic testing that can be applied in multiple areas, e.g., forensic screening, paternity and prenatal screening and genetic mapping.

A still further object is to provide an improved method for conducting a PCR procedure using an effective amount of a nucleotide according to the present invention and to provide an PCR assay kit

comprising an effective amount of a nucleotide according to the present invention and ancillary PCR reagents.

Brief Description of Drawings

5 Figure 1 relates to a nucleotide sequence according to SEQ ID NO:1.

 Figure 2 relates to a nucleotide sequence according to SEQ ID NO:2.

10 Figure 3 relates to a nucleotide sequence according to SEQ ID NO:3.

 Figure 4 relates to a nucleotide sequence according to SEQ ID NO:4.

 Figure 5 relates to a nucleotide sequence according to SEQ ID NO:5.

15 Figure 6 relates to a nucleotide sequence according to SEQ ID NO:6.

 Figure 7 relates to a nucleotide sequence according to SEQ ID NO:7.

20 Figure 8 relates to a nucleotide sequence according to SEQ ID NO:8.

 Figure 9 relates to a nucleotide sequence according to SEQ ID NO:9.

 Figure 10 relates to a nucleotide sequence according to SEQ ID NO:10.

25 Figure 11 relates to a nucleotide sequence according to SEQ ID NO:11.

 Figure 12 relates to a nucleotide sequence according to SEQ ID NO:12.

30 Figure 13 relates to a nucleotide sequence according to SEQ ID NO:13.

 Figure 14 relates to a nucleotide sequence according to SEQ ID NO:14.

Figure 15 relates to a nucleotide sequence according to SEQ ID NO:15.

Figure 16 relates to a nucleotide sequence according to SEQ ID NO:16.

5 Figure 17 relates to a nucleotide sequence according to SEQ ID NO:17.

Figure 18 relates to a nucleotide sequence according to SEQ ID NO:18.

10 Figure 19 relates to a nucleotide sequence according to SEQ ID NO:19.

Figure 20 relates to a nucleotide sequence according to SEQ ID NO:20.

Figure 21 relates to a nucleotide sequence according to SEQ ID NO:21.

15 Figure 22 relates to a nucleotide sequence according to SEQ ID NO:22.

Figure 23 relates to a nucleotide sequence according to SEQ ID NO:23.

20 Figure 24 relates to a nucleotide sequence according to SEQ ID NO:24.

Figure 25 relates to a nucleotide sequence according to SEQ ID NO:25.

Figure 26 relates to a nucleotide sequence according to SEQ ID NO:26.

25 Figure 27 relates to a nucleotide sequence according to SEQ ID NO:27.

Figure 28 relates to a nucleotide sequence according to SEQ ID NO:28.

30 Figure 29 relates to a nucleotide sequence according to SEQ ID NO:29.

Figure 30 relates to a nucleotide sequence according to SEQ ID NO:30.

Figure 31 relates to a nucleotide sequence according to SEQ ID NO:31.

Figure 32 relates to a nucleotide sequence according to SEQ ID NO:32.

Figure 33 relates to a nucleotide sequence according to SEQ ID NO:33.

5 Figure 34 relates to a nucleotide sequence according to SEQ ID NO:34.

Figure 35 relates to a nucleotide sequence according to SEQ ID NO:35.

10 Figure 36 relates to a nucleotide sequence according to SEQ ID NO:36.

Figure 37 relates to a nucleotide sequence according to SEQ ID NO:37.

Figure 38 relates to a nucleotide sequence according to SEQ ID NO:38.

15 Figure 39 relates to a nucleotide sequence according to SEQ ID NO:39.

Figure 40 relates to a nucleotide sequence according to SEQ ID NO:40.

20 Figure 41 relates to a nucleotide sequence according to SEQ ID NO:41.

Figure 42 relates to a nucleotide sequence according to SEQ ID NO:42.

Figure 43 relates to a nucleotide sequence according to SEQ ID NO:43.

25 Figure 44 relates to a nucleotide sequence according to SEQ ID NO:44.

Figure 45 relates to a nucleotide sequence according to SEQ ID NO:45.

30 Figure 46 relates to a nucleotide sequence according to SEQ ID NO:46.

Figure 47 relates to a nucleotide sequence according to SEQ ID NO:47.

Figure 48 relates to a nucleotide sequence according to SEQ ID NO:48.

Figure 49 relates to a nucleotide sequence according to SEQ ID NO:49.

Figure 50 relates to a nucleotide sequence according to SEQ ID NO:50.

5 Figure 51 relates to a nucleotide sequence according to SEQ ID NO:51.

Figure 52 relates to a nucleotide sequence according to SEQ ID NO:52.

10 Figure 53 relates to a nucleotide sequence according to SEQ ID NO:53.

Figure 54 relates to a nucleotide sequence according to SEQ ID NO:54.

Figure 55 relates to a nucleotide sequence according to SEQ ID NO:55.

15 Figure 56 relates to a nucleotide sequence according to SEQ ID NO:56.

Figure 57 relates to a nucleotide sequence according to SEQ ID NO:57.

20 Figure 58 relates to a nucleotide sequence according to SEQ ID NO:58.

Figure 59 relates to a nucleotide sequence according to SEQ ID NO:59.

Figure 60 relates to a nucleotide sequence according to SEQ ID NO:60.

25 Figure 61 relates to a nucleotide sequence according to SEQ ID NO:61.

Figure 62 relates to a nucleotide sequence according to SEQ ID NO:62.

30 Figure 63 relates to a nucleotide sequence according to SEQ ID NO:63.

Best Mode for Carrying out the Invention

The present invention provides a fast and accurate test for measuring subtle genetic differences in

individuals by way of genetic testing. The invention further relates to polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms) that can be used for human individualization. The invention further relates to 27 other polymorphic markers useful for human individualization. Applications for the technique and markers according to the invention are for example, in forensic screening, in paternity and prenatal screening as well as in genetic mapping.

The invention relates to polymorphic markers (two tetranucleotide, one dinucleotide repeat polymorphisms and 27 other unique polymorphic markers) that are useful for human individualization of forensic screen, and for paternity and prenatal screening as well as genetic mapping. The markers according to the present invention have high polymorphism information content (PIC) values. The first three markers are characterized by sets of oligonucleotide primers as follows:

1. Set 1, PIC 0.92
 - a. A nucleotide sequence according to SEQ ID NO:1
 - b. A nucleotide sequence according to SEQ ID NO:2
2. Set 2, PIC 0.91
 - a. A nucleotide sequence according to SEQ ID NO:3
 - b. A nucleotide sequence according to SEQ ID NO:4
3. Set 3, PIC 0.92
 - a. A nucleotide sequence according to SEQ ID NO:5

- b. A nucleotide sequence according to SEQ ID NO:6.

5 These polymorphic markers (two tetranucleotide and one dinucleotide repeat polymorphisms which are also accompanied by beginning and ending nucleotide sequences) that can be used for human individualization are further characterized by the following marker sequences.

10 1. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:7.

2. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:8.

3. A nucleotide sequence having a repeat polymorphism according to SEQ ID NO:9.

15 Since a polymorphic marker and an index locus occur as a "pair", attaching a primer oligonucleotide according to the present invention to the polymorphic marker allows PCR amplification of the segment pair. The amplified DNA segment can then be resolved by
20 electrophoresis and autoradiography. A resulting autoradiography can then be analyzed for its similarity to another DNA segment autoradiography. Following the PCR amplification procedure, electrophoretic motility enhancing DNA analogs may optionally be used to
25 increase the accuracy of the electrophoresis step.

Twenty-seven other primary pair sequences for detecting unique polymorphisms are sequences according to SEQ ID NO:10 through SEQ ID NO:63.

30 The described polymorphisms are useful for human sample individualization, because of their high PIC values. Since the described polymorphisms are based on the polymerase chain reaction, only minute amounts of genomic DNA are required for each test. The target sequences range from 69-260 bps in length so that high

molecular weight DNA is not necessary and common problems such as shearing of DNA will have minimal impact on the performance of the assay. The assay is easy to perform and results can be obtained within 24 hours. Microsatellite repeat polymorphisms have been shown to be useful tools in DNA analysis. The 27 polymorphisms described here are original and are based on previously sequenced human genes. The most commonly used technique in forensic screening is based on minisatellite markers in distinction to the PCR able microsatellites described here.

The 27 markers are characterized by sets of oligonucleotide primers as follows:

Pair #	Locus	Chromosomal Location	Primer SEQ ID NO:	Heteroz	PIC	Size	Repeat	No. of alleles
1A	Int-2	11q13	10,11	84.6%	0.79	161-177	(TG) ₅ TC(TG) ₁₆	9
2A	PLA-AZ	12	12,13	73.3%	0.76	122-137	(TTA) ₁₆	6
3A	FABP2	4q28-q31	14,15	64%	0.64	99-117	(TTA) ₁₃	6
4A	THROO1	15q15	16,17	60%	0.58	165-181	(CT) ₁₄	9
5A	CYAP450	15q21.1	18,19	91.3%	0.67	175-199	(TTTA) ₈	5
6A	GCG	2q36-q37	20,21	88%	0.77	142-172	(GA) ₁₉	11
7A	IL-9	5q	22,23	62.5%	0.75	127-139	(TG) ₂₀	7
8A	CSTP1	20	24,25	61%	0.58	123-141	(GT) ₁₅	
9A	ANKYRIN	8p11.1-21.1	26,27	54%	0.45	107-113	(AC) ₁₄	4
10A	CD-19	16	28,29	40%	0.39	79-91	(GT) ₁₇	7
11A	C-fms	5q33.3-34	30,31	86%	0.85	95-127	(GT) ₂₆	10
12A	CD 8	2p12	32,33	71%	0.66	138-170	(AC) ₁₄	7
13A	CYP2D7-8	22	34,35	80%	0.78	98-116	(GT) ₁₈	10
14A	W 30	7q	36,37	74%	0.72			11
15A	HMG-14	21	38,39	69%	0.67	69-93	(GT) ₁₉	10
16A	RHO	3	40,41	72%	0.68	145-169		5
17A	PFKL	21q22.3	42,43	70%	0.66	129-145	(AC) ₁₆	7
18A	HSFLT	13q12	44,45	51%	0.49	164-186	(TG) ₂₁	8
19A	HSNYHO1	14	46,47	66%	0.60	90-102	(GT) ₁₅	6
20A	HSATPSY1	12p13-qter	48,49	60%	0.54	111-117	(GT) ₁₁	4
21A	CPES PPS	15q25-qter	50,51	75%	0.70	143-163	(ATT) ₁₁	6
22A	DHFRP2	6	52,53	70%	0.66	157-173	(AAAC) ₇	5
23A	CRYG1	2q34-35	54,55	68%	0.61	117-126	(AAC) ₉	4
24A	F13A1	6p24-25	56,57	78%	0.75	180-230	(AAAG) ₇	8
25A	TRM1	6p23-q12	58,59	54%	0.50	174-186	(AAC) ₈	5
26A	II-D	6	60,61	81%	0.78	185-206	(CAG) ₁₈	
27A	TH	11p15.5-pl5	62,63	78%	0.75	244-260	(TCAT) ₉	5

Also, the invention relates to a method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to according to the invention as set forth above, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of

- a) a nucleotide sequence having the sequence as set forth in SEQ ID NO:1 and a nucleotide sequence as set forth in SEQ ID NO:2;
- b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4;
- c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6;
- d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11;
- e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13;
- f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15;
- g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17;
- h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19;
- i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21;

j) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23;

5 k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25;

l) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27;

10 m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29;

n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31;

15 o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33;

p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35;

q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37;

25 r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39;

s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41;

30 t) a nucleotide sequence having the sequence as set forth in SEQ ID NO:42 and a nucleotide sequence as set forth in SEQ ID NO:43;

- u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO:45;
- 5 v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO:47;
- w) a nucleotide sequence having the sequence as set forth in SEQ ID NO:48 and a nucleotide sequence as set forth in SEQ ID NO:49;
- 10 x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51;
- y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53;
- 15 z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55;
- aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57;
- 20 bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59;
- cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61;
- 25 dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63.
- 30

Therefore, the invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms

selected from the group consisting of a sequence according to SEQ ID NO:7, a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises

- 5 a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing,
- b. amplifying said segments by a PCR procedure using a pair of oligonucleotide primers capable of
- 10 amplifying said polymorphism containing segments,
- c. resolving the amplified segments using page gels electrophoresis, and
- d. comparing the resolved segments by autoradiography to observe the differences in migration
- 15 patterns due to length variation.

Preferably, the invention further relates to an assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms

20 selected from the group consisting of a sequence according to SEQ ID NO:7, a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises

- 25 a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing,
- b. amplifying said segments by a PCR procedure using the pair of oligonucleotide primers selected from the group consisting of a sequence according to SEQ ID
- 30 NO:1, a sequence according to SEQ ID NO:2, a sequence according to SEQ ID NO:3, a sequence according to SEQ ID NO:4, a sequence according to SEQ ID NO:5, or a sequence according to SEQ ID NO:6,

c. resolving the amplified segments using page gels electrophoresis, and

d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation.

5 Still further, the invention relates to an assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to the invention as set forth above, wherein the nucleotide is part of a primer pair of
10 nucleotides selected from the group of nucleotide pairs consisting of

a) a nucleotide sequence having the sequence as set forth in SEQ ID NO:1 and a nucleotide sequence as set forth in SEQ ID NO:2;

15 b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and

c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6,

20 d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11;

25 e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13;

f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15;

30 g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17;

h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19;

5 i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21;

j) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23;

10 k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25;

15 l) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27;

m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29;

20 n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31;

o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33;

25 p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35;

30 q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37;

r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39;

- s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41;
- 5 t) a nucleotide sequence having the sequence as set forth in SEQ ID NO:42 and a nucleotide sequence as set forth in SEQ ID NO:43;
- u) a nucleotide sequence having the sequence as set forth in SEQ ID NO:44 and a nucleotide sequence as set forth in SEQ ID NO:45;
- 10 v) a nucleotide sequence having the sequence as set forth in SEQ ID NO:46 and a nucleotide sequence as set forth in SEQ ID NO:47;
- w) a nucleotide sequence having the sequence as set forth in SEQ ID NO:48 and a nucleotide sequence as set forth in SEQ ID NO:49;
- 15 x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51;
- y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53;
- 20 z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55;
- 25 aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57;
- bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59;
- 30 cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; and

dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63;

5 wherein said nucleotide is in combination with an effective amount of ancillary PCR reagents.

Accordingly, the above described polymorphisms are useful for human sample individualization, because of their high PIC values. Since the described polymorphic systems are based on the polymerase chain reaction (PCR), only minute (40 nanograms) amounts of genomic DNA are required for each test. The target sequences range from 92 to 310 base pairs so that high molecular weight DNA is not necessary, and common problems such as shearing of DNA will have minimal impact on the performance of the assay. The assay is easy to perform and results can be obtained within 24 hours. It is not uncommon for results to be available within 3-4 hours. By comparison, the prior art methods require a number of days before results are available, usually 3-4 days are required.

20 Also, the polymorphism corresponding to 1A-27A as described above and characterizes by their 27 primer pairs according to SEQ ID NO:10-SEQ NO:63 are useful for human sample individualization evaluation because of their high PIC values.

25 Further, the assay according to the invention is able to detect very small differences in nucleotide sequences. A single omission or addition of the repeat sequence will change the mobility due to the electrical nature and molecular weight of the target nucleotide sequence. These differences are clearly visible on the autoradiographs after electrophoresis.

30 Microsatellite repeat polymorphisms have been shown to be useful tools in DNA analysis. The three

polymorphisms described here are original and are based on previously sequenced genes. The two tetranucleotide repeat markers described, can be scored easily since allele sizes differ by four base pairs. The most commonly used technique used in forensic screening is based on minisatellite markers, in distinction to the PCR able microsatellites described in the present invention.

The general PCR technique step is conducted generally as described in U.S. Patent No. 4,683,195 to Mullis et al and U.S. Patent No. 4,683,202 to Mullis et al, which are hereby incorporated by reference thereto. Further, electrical motility enhancing DNA analogs can optionally be used during the replication and amplification PCR procedure.

The degree of polymorphism in the genetic segments according to the present invention, which polymorphisms yield highly informative identification test results, is surprising and unexpected. The high PIC value (approximately 0.9) is totally unexpected.

Accordingly, the use of a PCR procedure and PCR primers pairs, such as those primer sequences according to SEQ ID NO:1 to SEQ ID NO:6, to detect the polymorphism DNA segment according to the present invention yields excellent results. Further use of primer sequences corresponding to SEQ ID NO:10 through SEQ ID NO:63 to detect the polymorphism yields excellent results. Such results are sufficiently accurate and informative to accurately identify DNA segments and determine degrees of relationship between DNA segments of individuals. Moreover, conducting three sets of PCR procedures on the same DNA segment samples while using a different PCR primer pair according to the present invention for each of the

three procedures yields extraordinarily accurate and informative test results. Comparison of the three sets of test results data provides extremely accurate DNA segment identification.

5 The following examples are provided to more specifically describe the invention which is not limited to the following examples.

 The described oligonucleotide primers are used to amplify the target sequences using PCR, under the
10 following conditions:

Example 1

 The samples are of DNA are prepared as follows.

 60ng of genomic DNA are used as template for PCR with 80ng of each oligonucleotide primer, 0.6 units of
15 Taq Polymerase 50mM KCL, 10mM Tris (pH 8.3), 1.5mM MgCl₂, 0.01% gelatin, 200uM of each dGTP, dATP, dTTP, 2.5uM dCTP and 10 microcuries of alpha P32 dCTP., in a final reaction volume of 15 microliters. The samples are overlaid with 15 microliters of mineral oil to
20 prevent evaporation.

Example 2

 PCR is performed for each of the samples and primers described in Example 1, above.

 PCR is performed in a Techne MW-1 microplate thermocycler under the following conditions
25 denaturation of 94 degrees C for 1.4 min., annealing at 55 degrees C for 2 min., and extension at 72 degrees C for 2 min. The cycle is repeated 30 times with a final extension at 72 degrees C for 10 min.

30 Example 3

 The amplified DNA segments from each of the samples described in Example 2 above are resolved by electrophoresis as follows.

Two microliters of each PCR reaction mixture sample are electrophoresed on a 6% PAGE sequencing gel and visualized by autoradiography. Exposure times for the autoradiography range from 3-16 hours.

5 The foregoing description of the specific
embodiments will so fully reveal the general nature of
the invention that others can, by applying current
knowledge, readily modify and/or adapt for various
10 applications such specific embodiments without
departing from the generic concept and therefore such
adaptations are intended to be comprehended within the
meaning and range of equivalents of a disclosed
embodiment. It is to be understood that the
15 phraseology or terminology employed herein is for the
purposes of description only and not of limitation.

Claims

1. A nucleotide sequence selected from the group consisting of a sequence according to SEQ ID NO:1, a sequence according to SEQ ID NO:2, a sequence according to SEQ ID NO:3, a sequence according to SEQ ID NO:4, a sequence according to SEQ ID NO:5, or a
5 sequence according to SEQ ID NO:6.

2. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:1.

3. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:2.

4. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:3.

5. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:4.

6. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:5.

7. A nucleotide sequence according to claim 1, wherein the sequence is a sequence according to SEQ ID NO:6.

8. A method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to claim 1, wherein the nucleotide is part of a primer pair of nucleotides
5 selected from the group of nucleotide pairs consisting of

- a) a nucleotide sequence having the sequence as set forth in SEQ ID NO:1 and a nucleotide sequence as set forth in SEQ ID NO:2;
- 10 b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and
- c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as
15 set forth in SEQ ID NO:6.

9. An assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms wherein said genetic material comprises a sequence
5 selected from the group consisting of a sequence according to SEQ ID NO:7, a sequence according to SEQ ID NO:8 and a sequence according to SEQ ID NO:9, which comprises

- a. obtaining nucleotide segments comprising said
10 repeat polymorphisms in an amount effective for testing,
- b. amplifying said segments by a PCR procedure using a pair of oligonucleotide primers capable of amplifying said polymorphism containing segments,

15 c. resolving the amplified segments using page gels electrophoresis, and

 d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation.

20 10. An assay according to claim 9, wherein said pair of oligonucleotide primers is selected from the group consisting of a sequence according to SEQ ID NO:1, a sequence according to SEQ ID NO:2, a sequence according to SEQ ID NO:3, a sequence according to SEQ
25 ID NO:4, a sequence according to SEQ ID NO:5, or a sequence according to SEQ ID NO:6.

 11. An assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to claim 1, wherein the nucleotide is part of a primer pair of
5 nucleotides selected from the group of nucleotide pairs consisting of

 a) a nucleotide sequence having the sequence as set forth in SEQ ID NO:1 and a nucleotide sequence as set forth in SEQ ID NO:2;

10 b) a nucleotide sequence having the sequence as set forth in SEQ ID NO:3 and a nucleotide sequence as set forth in SEQ ID NO:4; and

 c) a nucleotide sequence having the sequence as set forth in SEQ ID NO:5 and a nucleotide sequence as set forth in SEQ ID NO:6, in combination with an
15 effective amount of ancillary PCR reagents.

 12. A nucleotide sequence selected from the group consisting of a sequence according to SEQ ID NO:10 through SEQ ID NO:63.

13. A method for conducting a PCR procedure comprising using an effective amount of at least one nucleotide according to claim 12, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of

- 5 d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11;
- 10 e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13;
- f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15;
- 15 g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17;
- h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19;
- 20 i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21;
- j) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23;
- 25 k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25;
- 30 l) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27;

- 35 m) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:28 and a nucleotide sequence as
set forth in SEQ ID NO:29;
- n) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:30 and a nucleotide sequence as
set forth in SEQ ID NO:31;
- 40 o) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:32 and a nucleotide sequence as
set forth in SEQ ID NO:33;
- p) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:34 and a nucleotide sequence as
45 set forth in SEQ ID NO:35;
- q) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:36 and a nucleotide sequence as
set forth in SEQ ID NO:37;
- r) a nucleotide sequence having the sequence as
50 set forth in SEQ ID NO:38 and a nucleotide sequence as
set forth in SEQ ID NO:39;
- s) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:40 and a nucleotide sequence as
set forth in SEQ ID NO:41;
- 55 t) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:42 and a nucleotide sequence as
set forth in SEQ ID NO:43;
- u) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:44 and a nucleotide sequence as
60 set forth in SEQ ID NO:45;
- v) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:46 and a nucleotide sequence as
set forth in SEQ ID NO:47;
- w) a nucleotide sequence having the sequence as
65 set forth in SEQ ID NO:48 and a nucleotide sequence as
set forth in SEQ ID NO:49;

- x) a nucleotide sequence having the sequence as set forth in SEQ ID NO:50 and a nucleotide sequence as set forth in SEQ ID NO:51;
- 70 y) a nucleotide sequence having the sequence as set forth in SEQ ID NO:52 and a nucleotide sequence as set forth in SEQ ID NO:53;
- z) a nucleotide sequence having the sequence as set forth in SEQ ID NO:54 and a nucleotide sequence as set forth in SEQ ID NO:55;
- 75 aa) a nucleotide sequence having the sequence as set forth in SEQ ID NO:56 and a nucleotide sequence as set forth in SEQ ID NO:57;
- bb) a nucleotide sequence having the sequence as set forth in SEQ ID NO:58 and a nucleotide sequence as set forth in SEQ ID NO:59;
- 80 cc) a nucleotide sequence having the sequence as set forth in SEQ ID NO:60 and a nucleotide sequence as set forth in SEQ ID NO:61; and
- 85 dd) a nucleotide sequence having the sequence as set forth in SEQ ID NO:62 and a nucleotide sequence as set forth in SEQ ID NO:63;

14. An assay for measuring the subtle differences in genetic material regarding an added or omitted set of dinucleotide or tetranucleotide repeat polymorphisms wherein said genetic material comprises a sequence
- 5 characterized by primer pairs 1A-27A, which comprises
- a. obtaining nucleotide segments comprising said repeat polymorphisms in an amount effective for testing,
- b. amplifying said segments by a PCR procedure
- 10 using a pair of oligonucleotide primers capable of amplifying said polymorphism containing segments,

c. resolving the amplified segments using page gels electrophoresis, and

15 d. comparing the resolved segments by autoradiography to observe the differences in migration patterns due to length variation.

15 15. An assay according to claim 3, wherein said pair of oligonucleotide primers is selected from the group consisting of a sequence according to SEQ ID NO:10 through SEQ ID NO:63.

5 16. An assay kit for conducting a PCR procedure comprising an effective amount of at least one nucleotide having a sequence according to claim 1, wherein the nucleotide is part of a primer pair of nucleotides selected from the group of nucleotide pairs consisting of

d) a nucleotide sequence having the sequence as set forth in SEQ ID NO:10 and a nucleotide sequence as set forth in SEQ ID NO:11;

10 e) a nucleotide sequence having the sequence as set forth in SEQ ID NO:12 and a nucleotide sequence as set forth in SEQ ID NO:13;

15 f) a nucleotide sequence having the sequence as set forth in SEQ ID NO:14 and a nucleotide sequence as set forth in SEQ ID NO:15;

g) a nucleotide sequence having the sequence as set forth in SEQ ID NO:16 and a nucleotide sequence as set forth in SEQ ID NO:17;

20 h) a nucleotide sequence having the sequence as set forth in SEQ ID NO:18 and a nucleotide sequence as set forth in SEQ ID NO:19;

- i) a nucleotide sequence having the sequence as set forth in SEQ ID NO:20 and a nucleotide sequence as set forth in SEQ ID NO:21;
- 25 j) a nucleotide sequence having the sequence as set forth in SEQ ID NO:22 and a nucleotide sequence as set forth in SEQ ID NO:23;
- k) a nucleotide sequence having the sequence as set forth in SEQ ID NO:24 and a nucleotide sequence as set forth in SEQ ID NO:25;
- 30 l) a nucleotide sequence having the sequence as set forth in SEQ ID NO:26 and a nucleotide sequence as set forth in SEQ ID NO:27;
- m) a nucleotide sequence having the sequence as set forth in SEQ ID NO:28 and a nucleotide sequence as set forth in SEQ ID NO:29;
- 35 n) a nucleotide sequence having the sequence as set forth in SEQ ID NO:30 and a nucleotide sequence as set forth in SEQ ID NO:31;
- o) a nucleotide sequence having the sequence as set forth in SEQ ID NO:32 and a nucleotide sequence as set forth in SEQ ID NO:33;
- 40 p) a nucleotide sequence having the sequence as set forth in SEQ ID NO:34 and a nucleotide sequence as set forth in SEQ ID NO:35;
- 45 q) a nucleotide sequence having the sequence as set forth in SEQ ID NO:36 and a nucleotide sequence as set forth in SEQ ID NO:37;
- r) a nucleotide sequence having the sequence as set forth in SEQ ID NO:38 and a nucleotide sequence as set forth in SEQ ID NO:39;
- 50 s) a nucleotide sequence having the sequence as set forth in SEQ ID NO:40 and a nucleotide sequence as set forth in SEQ ID NO:41;

- 55 t) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:42 and a nucleotide sequence as
set forth in SEQ ID NO:43;
- u) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:44 and a nucleotide sequence as
60 set forth in SEQ ID NO:45;
- v) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:46 and a nucleotide sequence as
set forth in SEQ ID NO:47;
- w) a nucleotide sequence having the sequence as
65 set forth in SEQ ID NO:48 and a nucleotide sequence as
set forth in SEQ ID NO:49;
- x) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:50 and a nucleotide sequence as
set forth in SEQ ID NO:51;
- 70 y) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:52 and a nucleotide sequence as
set forth in SEQ ID NO:53;
- z) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:54 and a nucleotide sequence as
75 set forth in SEQ ID NO:55;
- aa) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:56 and a nucleotide sequence as
set forth in SEQ ID NO:57;
- bb) a nucleotide sequence having the sequence as
80 set forth in SEQ ID NO:58 and a nucleotide sequence as
set forth in SEQ ID NO:59;
- cc) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:60 and a nucleotide sequence as
set forth in SEQ ID NO:61; and
- 85 dd) a nucleotide sequence having the sequence as
set forth in SEQ ID NO:62 and a nucleotide sequence as
set forth in SEQ ID NO:63;

wherein said effective amount of said nucleotide
is in combination with an effective amount of ancillary
90 PCR reagents.

1/8
FIGURE 1

AATCTGGGCG ACAAGAGTGA

20

FIGURE 2

ACATCTCCCC TACCGCTATA

20

FIGURE 3

TCCAGCCTCG GAGACAGAAT

20

FIGURE 4

AGTCCTTTCT CCAGAGCAGG T

21

FIGURE 5

GCCAGTGATG CTAAAGGTTG

20

FIGURE 6

AACATACGTG GCTCTATGCA

20

AATCTGGGCG ACAAGAGTGA AACTCCGTCA AAAGAAAGAA AGAAAGAGAC	50
AAAGAGAGTT AGAAAGAAAG AAAGAGAGAG AGAGAGAAAG GAAGGAAGGA	100
AGAAAAAGAA AGAAAAAGAA AGAAAGAGAA AGAAAGAAAG AGAAAGAAAG	150
AAAGAAAGAA AGAAAGAAAG AAAGAAAGAA AGAAAGAAAA AGAAAGAAAG	200
AAAGAAAGAA AGAAAGAAAG AAAGAAAGAA AGAAAGAAAG AAAGAAAGGA	250
AGGAAAGAAA GAGCAAGTTA CTATAGCGGT AGGGGAGATG T	291

FIGURE 8

GCCAGTGATG CTAAAGGTTG TATTGCATAT ATACATATAT ATATATATAT	50
ATATATATAT ATATATATAT ATATATATAT ATATATATAT TTTAATTGGA	100
TAGTATTGTG CATAGAGCCA CGTATGTT	128

FIGURE 9

TCCAGCCTCG GAGACAGAAT GAGACTCCAT CAAAAACAAG AAAGAAAGAA	50
AGACAAAGAG AGAAAGAAAG AAAGAAAGAA AGAAAGAAAG AGAGAGAGAG	100
AGAGAGAGAG AGAAAGAAAG AAAGAAAGAA AGAAAGAAAG AAAGAAAGAA	150
AGAAAGAAAG AAAGAAAGAA GGAAAGAAAG AAAGGAACT AAAATAACTA	200
AATAACTGAG TAGCACCACA CCACCTGCTC TGGAGAAAGG ACT	243

FIGURE 10

TTTCTGGGTG TGTCTGAAT	19
----------------------	----

FIGURE 11

ACACAGTTGC TCTAAAGGGT	20
-----------------------	----

3/8

FIGURE 12

CTAGGTTGTA AGCTCCATGA

20

FIGURE 13

TTGAGCACTT ACTCTGTGCC

20

FIGURE 14

AACTCAGAAC AGTGCCTGAC

20

FIGURE 15

ATTTCCTCA AGGCTCCAGG T

21

FIGURE 16

CTGATCTTGC TCACCTTCGA

20

FIGURE 17

GCGTTTGCTG AAATGAAGGA

20

FIGURE 18

GCAGGTACTT AGTTAGCTAC

20

FIGURE 19

TTACAGTGAG CCAAGGTCGT

20

FIGURE 20

TTTGTCTGGA TAGACTGGAG

20

4/8

FIGURE 21

CCATCTTCCT GTGGCTGTA

19

FIGURE 22

CTAATGCAGA GATTTAGGGC

20

FIGURE 23

GTGGTGTAAG GACTGCATAG

20

FIGURE 24

ATGTGACTGA TGTGGGTCAG

20

FIGURE 25

CATCTGCACT CATGCTCCAT

20

FIGURE 26

TCCCAGATCG CTCTACATGA

20

FIGURE 27

CACAGCTTCA GAAGTCACAG

19

FIGURE 28

GAGCAATGTT GCTTAGGATG

20

FIGURE 29

TGGAAGTGTC ACTGGCATGT

20

5/8

FIGURE 30

TGTGTCCAGC CTTAGTGTGC A

21

FIGURE 31

TCATCACTTC CAGAATGTGC

20

FIGURE 32

ACTGCCTCAT CCAGTTTCAG

20

FIGURE 33

GAGCAGGCAC TTGTTAGATG

20

FIGURE 34

CCTCTTGGCT CTAACAGCAA

20

FIGURE 35

AGCAAGACCC TGTCTCAAGA

20

FIGURE 36

CAAGGCCCAT CTTCAGTAGA

20

FIGURE 37

CCTTCTCACT CCTTTACTAG

20

FIGURE 38

GAAGACTGAG GAGGTCAGAA

20

6/8

FIGURE 39

CTACTGTTCA GAGTCAAAGC

20

FIGURE 40

TGCCCCACAT TAGGATGCAT

20

FIGURE 41

AGGGACACGA ATCAGATCAG

20

FIGURE 42

GTGGTACCTC ATTGTGGCTA

20

FIGURE 43

AGGCATCCTT GTGCTGACAT

20

FIGURE 44

TTTGGCCGAC AGTGGTGTA

20

FIGURE 45

AGGACCAAAC CATGTCTGTC

20

FIGURE 46

CTGCATCTGA GCATATGGGA

20

FIGURE 47

CATTCAGACT ATGCAGGCTT

20

7/8

FIGURE 48

CTGGGACTAC TGGCACATG

19

FIGURE 49

GGCAACGTGG TGAAACCTT

19

FIGURE 50

GGAAGATGGA GTGGCTGTTA

20

FIGURE 51

CTCCAGCCTG GCGAAAGAAT

20

FIGURE 52

GTAAGACTTT TGGAGCCATT

20

FIGURE 53

TTCAGGGAGA ATGAGATGGG

20

FIGURE 54

GACAGAGTGA GACTCCATCT

20

FIGURE 55

GATCCTATCT TCTCAGGAGG

20

FIGURE 56

GAGGTTGCAC TCCAGCCTTT

20

8/8

FIGURE 57

ATGCCATGCA GATTAGAAA

19

FIGURE 58

GGAAAGAAAC AGTGAAAGA

19

FIGURE 59

ATCCATCGAC CTCTGGGTTA

20

FIGURE 60

GACCCACAG CCTATTCAGA

20

FIGURE 61

TTGACTGCTG AACGGCTGCA

20

FIGURE 62

CAGCTGCCCT AGTCAGCAC

19

FIGURE 63

GCTTCCGAGT GCAGGTCACA

20

A. CLASSIFICATION OF SUBJECT MATTER

IPC(5) : C07H 21/00; C12Q 1/68

US CL : 536/27; 435/6, 91

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 536/27; 435/6, 91

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CAS ONLINE, MEDLINE, APS

search terms: polymorphism, nucleic acid, polymerase chain reaction, tandem repeat

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	American Journal of Human Genetics, Volume 44, issued 1989, Weber et al., "Abundant Class of Human DNA Polymorphisms which can be Typed Using the Polymerase Chain Reaction", pages 388-396, see entire document.	1-16
Y	EMBO JOURNAL, Volume 2, No. 5, issued 1983, Moos et al., "Structure of Two Human Beta-Actin-related Processed Genes one of which is Located Next to a Simple Repetitive Sequence", pages 757-761, see entire document.	1-16
Y	Genomics, Volume 4, issued 1989, Chen et al., "The Human Growth Hormone Locus: Nucleotide Sequence, Biology, and Evolution", pages 479-497, see entire document.	1,4-5, 8-11
Y	US, A, 4,800,159 (Mullis et al.) 24 June 1989, column 3, lines 24-26.	11, 16

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

* Special categories of cited documents:	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be part of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Z" document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means	
"P" document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

20 August 1992

Date of mailing of the international search report

02 SEP 1992

 Name and mailing address of the ISA/
 Commissioner of Patents and Trademarks
 Box PCT
 Washington, D.C. 20231

Authorized officer

LISA T. BENNETT

Facsimile No. NOT APPLICABLE

Telephone No. (703) 308-3988

C (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	European Journal of Immunology, Volume 18, issued 1988, Dariavach et al., "Human Ig Superfamily CTLA-4 Gene: Chromosomal Localization and Identity of Protein Sequence Between Murine and Human CTLA-4 Cytoplasmic Domains", pages 1901-1905, see entire document.	1, 6-7, 8-11

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

THIS PAGE BLANK (USPTO)